Gene Therapy

Gene therapies to mitigate the effects of mutations that cause blindness are undergoing rapid development. Investigators have found that novel gene vectors reduce the risks associated with these procedures.

Study examining the role of IL-17A in patients with diabetes.

Investigators focus on biophysical method to study protein-protein interactions .

Results of a study analysing cytokine levels in the aqueous humour and serum of patients with nonproliferative diabetic retinopathy with and without diabetic macular oedema support further research investigating transforming growth factor-β-induced Gene Human Clone 30 (BIGH3) as a potential biomarker for DMO.

The FDA has granted Fast Track designation to MeiraGTx's AAV-CNGA3 gene therapy product candidate for the treatment of achromatopsia (ACHM).

Neurophth Therapeutics, Inc (Neurophth) and AAVnerGene Inc have announced the launch of a strategic partnership that will grant Neurophth global rights to mutually select adeno-associated virus (AAV) capsids for the creation of the next-generation ophthalmic gene therapy.

A new gene therapy for this patient population targets the ND4 gene mutation.

BIGH3 is an extracellular matrix protein that can act in an autocrine, paracrine manner.

Two teams of researchers from Gyroscope Therapeutics and the University of Pennsylvania are joining forces to explore gene therapy targets for three specific serious eye diseases.

The investigational RNA therapy is designed to address the underlying cause of Leber congenital amaurosis 10 due to a mutation in the CEP290 gene.

ViGeneron and Biogen this week have announced a global collaboration and licensing agreement in which the partners will develop and commercialize gene therapy products based on adeno-associated virus (AAV) vectors that treat inherited eye disease.

Nine pediatric patients with Leber congenital amaurosis show visual improvement in clinical trials.

With several clinical trials underway, ocular therapy is seen as having potential in the treatment of a number of gene-related diseases.

Patients with pathogenic variants experience lower VA tied to length of IS/OS junction.

In this roundtable, members of the Ophthalmology Times Europe® Editorial Advisory Board consider the top challenges and opportunities that they anticipate will affect ophthalmology in Europe in 2021.

Investigators reviewed visual acuity, multi-modal retinal imaging, electroretinography, family history.

Study examines use of fluocinolone acetonide for treating DME in patients.

This ability would unlock possibilities for repairing tissue damaged by disease

Intravitreal gene therapy continues to be well tolerated and shows robust efficacy

In study, treatment demonstrates promising biologic activity, safety profile

Patients underwent short-course, perioperative systemic immunosuppression prior to procedure

Investigators find that nanoparticles deliver gene therapy successfully in mice, rats.

Investigators find that nanoparticles deliver gene therapy successfully in mice, rats.